Bevacizumab and ranibizumab treatments for neovascularization from causes other than age‐related macular degeneration

Abstract Purpose To report the results of intravitreal bevacizumab (Avastin) and ranibizumab (Lucentis) treatment for ocular neovascularization from causes other than age‐related macular degeneration. Methods We performed a retrospective case note analysis of eyes who received intravitreal bevacizumab and ranibizumab for patients with ocular neovascularization. Repeated treatment occurred if there were signs of recurrence of disease activity. The main outcome measures were visual acuity, clinical signs and findings on optical coherence tomography and fluorescein angiography. Results Nine patients (10 eyes) were included in this study. Diagnoses included subfoveal choroidal neovascularization secondary to punctate inner choroidopathy (n=2), myopic degeneration (n=2), pseudoxanthoma elasticum (n=1). Others have proliferative diabetic retinopathy (n=2), central retinal vein occlusion (n=1), clinically significant macular oedema (n=1), Coat’s disease (n=1). The range of baseline visual acuity was from counting fingers to 6/9. The mean fellow‐up was 12 months; the mean number of injections in 9 eyes was 1.5. One eye had 12 injections. At the last fellow‐up, 9 eyes had improved or stable visual acuity. There were no complications reported. Conclusion Ocular neovascularization secondary to non AMD causes treated with intravitreous bevacizumab and ranibizumab responded favourably, despite varying underlying aetiologies.